E-Learning

US benchmark equity indexes were lower after midday Friday as markets looked forward to the Federal

BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024. Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed. For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections. Looking ahead

Ciena Corp (NYSE:CIEN) stock surged after BofA Securities upgraded it from Neutral to Buy and raised its price target from $70 to $95. Needham analyst Ryan Koontz maintained Ciena with a Buy and raised the price target from $80 to $95. Additionally, Northland Capital Markets, and Stifel raised their respective price targets on the stock. On Thursday, Ciena reported a fiscal fourth-quarter 2024 revenue decline of 0.5% to $1.12 billion, beating the analyst estimate of $1.10 billion. The adjusted E

BofA Securities analyst Peter T. Galbo upgraded General Mills, Inc. (NYSE:GIS) to Buy from Neutral, raising the price forecast to $80 from $78. The analyst suggests that General Mills is expected to return to organic sales growth at a faster and more sustainable rate compared to other center-store food peers. This growth will be driven by factors such as the re-acceleration in the Pet segment (specifically Blue Buffalo) and stabilization in North America Retail, as issues in the dough category a

We've already seen how the ease of smartphone transactions and impulsive late night behavior leads to trouble for young men.

Major U.S. indexes were slightly lower at midday Friday as markets pulled back from the post-election rally that sent them into record territory.

Money market account rates vary widely. So which banks are offering the best money market account rates today? Find out here.

As of Thursday, the average target for the S&P 500 index to close at the end of 2025 was 6,678.18, which would be a 10% rise from the index's Thursday close.

Elon Musk says the Securities and Exchange Commission wants him to pay a penalty or face charges involving what he disclosed — or failed to disclose — about his purchases of Twitter stock before he bought the social media platform in 2022. In a letter posted by Musk on the platform now called X, his lawyer Alex Spiro tells the outgoing SEC chairman, Gary Gensler, that the commission's demand for a monetary payment is a “misguided scheme” that won't intimidate Musk. The letter also alleges that the commission reopened an investigation this week into Neuralink, Musk's computer-to-human brain interface company.

On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial. Across all tumor types treated at the optimized RP2D (n=67),